Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $229 | In Stock | |
5 mg | $543 | In Stock | |
10 mg | $797 | In Stock |
Description | Atezolizumab is an antibody inhibitor, a humanized monoclonal antibody, IgG1, which targets PD-L1 and blocks the interaction of PD-L1 with PD-1. Atezolizumab has antitumor activity and promotes T-cells to attack tumor cells. |
Cell Research | Objective: Determine the binding of [111In]PD-L1-mAb to tumor cell lines. Cells: NCI-H2444(Lung Cancer cell line), MDAMB231(Breast Cancer cell line),etc. Concentrations: 1 μCi/100μl. Incubation Time: 1 h. Method: Incubating 1 μCi of [111In]PD-L1-mAb with 1×106cells (in triplicate for each cell line) for 1h at 37°C. PD-L1 blocking was performed by adding a 10-fold molar equivalent excess of the non-labeled mAb. After incubation, cells were washed three times with cold PBS prior to counting on an automated gamma counter. |
Molecular Weight | 145 kDa |
Cas No. | 1380723-44-3 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.